split-banner-image

FERTILITY, PREGNANCY AND BREAST CANCER

Understand fertility, pregnancy and breast cancer, including IVF, egg freezing, early menopause and recurrence risk in Australia.

A diagnosis of breast cancer can be particularly confronting for women who are still planning to have children or who are currently pregnant. Many women immediately wonder whether treatment will affect their fertility, whether pregnancy will still be possible in the future, or whether trying to conceive after treatment could increase the risk of cancer returning. 

The reassuring news is that many women can still have children after breast cancer treatment, and research continues to improve fertility options and pregnancy outcomes for women diagnosed during their reproductive years. Breast cancer can also occur during pregnancy, although this is uncommon, and specialised medical teams work carefully to protect both mother and baby, emphasising the importance of tailored pregnancy and breast cancer treatment. 

Understanding the relationship between fertility, pregnancy and breast cancer can help women make informed decisions about treatment and future family planning. This guide explains how breast cancer treatments may affect fertility, options such as egg freezing and IVF, pregnancy after treatment, and the specialist care available in Australia.  

How Breast Cancer Treatment Can Affect Fertility 

Some breast cancer treatments can affect the ovaries and the body’s ability to conceive. However, the impact varies widely depending on factors such as age, the type of treatment used, and how the ovaries respond. 

Chemotherapy and fertility

Chemotherapy works by targeting rapidly dividing cells. While this is effective against cancer cells, it can also affect healthy cells, including those in the ovaries that produce eggs. Different chemotherapies impact the ovaries to varying degrees. As a result, some women may experience: 

  • Temporary infertility 
  • Reduced fertility 
  • Permanent infertility in some cases 

Younger women generally have a higher chance of ovarian recovery after treatment compared with older women. 

Some women also experience early menopause, particularly if chemotherapy significantly affects ovarian function. 

Breast cancer treatment can also delay pregnancy plans. For some women, treatment may continue for several years, particularly if hormone therapy is recommended after chemotherapy or surgery. This delay can reduce fertility opportunities over time, especially as natural fertility declines with age. Discussing future family plans with your healthcare team before treatment begins can help you understand your options and consider fertility preservation if appropriate. 

Tamoxifen and fertility

Tamoxifen is a hormone therapy commonly used to reduce the risk of breast cancer returning. It is typically taken for five to ten years, which can delay pregnancy plans as pregnancy is not recommended whilst taking tamoxifen. 

Because fertility decisions are time-sensitive, it is important to discuss fertility preservation before breast cancer treatment begins. 

Research improving fertility options 

Australian researchers have played an important role in improving fertility outcomes for women with breast cancer. The POEMS clinical trial, led by Breast Cancer Trials, showed that a medication called Zoladex (Goserelin) can be used to temporarily suppress ovarian function during chemotherapy and help protect fertility in some women. 

This research has helped expand options for women who hope to have children after treatment. 

Women are also encouraged to explore resources from organisations such as Cancer Australia and Breast Cancer Network Australia (BCNA) when considering fertility planning. 

Early Menopause and Breast Cancer 

Some women experience early menopause as a result of breast cancer treatment. 

Early menopause occurs when the ovaries stop functioning before the age of 45. Chemotherapy can damage ovarian tissue, reducing the body’s ability to produce hormones and eggs. 

Symptoms of early menopause may include: 

  • Hot flushes 
  • Sleep disturbances 
  • Vaginal dryness 
  • Mood changes 
  • Reduced libido 

For younger women, the emotional impact of early menopause can be significant, particularly if they had hoped to have children in the future. Symptoms of menopause can also have a significant effect, impacting a woman’s ability to work, exercise and care for their family. 

Managing symptoms and understanding fertility implications are important parts of care. Women experiencing these effects may benefit from guidance from both oncology specialists and menopause or fertility experts. 

You can learn more in our guides on early-onset breast cancer, early menopause, and young women and breast cancer. 

Fertility and Breast Cancer Options

Several options are available to help preserve fertility before breast cancer treatment begins. These approaches are usually arranged quickly after diagnosis, before chemotherapy or other treatments start. 

Breast cancer and egg freezing

Egg freezing involves stimulating and then collecting mature eggs from the ovaries and storing them for future use. This allows women the possibility of pregnancy later, even if treatment affects ovarian function. 

Breast cancer and embryo freezing

Embryo freezing is similar to egg freezing but involves collecting and then fertilising the eggs with sperm before freezing them. This process is known as in vitro fertilization (IVF). 

This option is the most reliable and may be suitable for women who have a partner or who wish to use donor sperm. 

Ovarian tissue freezing (ovarian tissue cryopreservation)

Ovarian tissue freezing is an emerging fertility preservation technique. A small amount of ovarian tissue is removed and stored for later transplantation. The transplanted ovarian tissue is then able to produce both eggs to restore fertility, as well hormones to prevent early menopause. 

This approach is newer but still considered an option to preserve fertility and may offer hope for some women. 

Ovarian suppression during chemotherapy 

Medications can sometimes be used during chemotherapy to temporarily suppress ovarian activity, which may reduce the risk of treatment-related infertility. 

The POEMS clinical trial conducted by Breast Cancer Trials, helped demonstrate the potential benefit of this approach. 

Timing and specialist referral 

Fertility preservation treatments usually need to be completed before chemotherapy begins, so early referral to a fertility specialist is important. 

In Australia, access to fertility services may be supported through Medicare and private fertility clinics, depending on the procedure. 

You can listen to our Q&A about breast cancer and fertility, moderated by Author and Journalist Annabel Crabb, here. 

Pregnancy After Breast Cancer – Is It Safe? 

Many women worry that pregnancy after breast cancer could increase the risk of recurrence.  

While individual circumstances vary, pregnancy after breast cancer does not increase the risk of cancer returning for most women. 

In many cases, survival outcomes for women who become pregnant after treatment are similar to those who do not. This is also true for patients with hormone receptor positive breast cancers and those with BRCA 1 or BRCA 2 mutations. 

Research shows that babies born to women who have previously had breast cancer generally do just as well as those born to women without a history of cancer. They experience normal growth and development, with no increased risk of birth defects, stillbirth, neonatal death or other major health problems. 

Doctors often recommend waiting around two years after treatment before trying to conceive, as this is when the breast cancer recurrence risk is typically highest. However, timing recommendations vary depending on the individual situation. 

Pausing endocrine therapy to try for pregnancy 

For some women with hormone receptor-positive breast cancer, endocrine therapy such as tamoxifen is recommended for five to ten years after treatment. This can delay plans to start or grow a family. 

The international POSITIVE clinical trial is investigating whether temporarily pausing endocrine therapy to attempt pregnancy is safe. Early results suggest that a planned interruption does not increase the short-term risk of breast cancer recurrence. However, longer-term follow-up is still underway, and any decision to pause treatment should be made in consultation with your treating team. 

Breast Cancer and Reproductive Concerns 

Even with reassuring research, many women experience anxiety about pregnancy after breast cancer. 

Common concerns include: 

  • Fear of cancer recurrence 
  • Concerns about hormone exposure during pregnancy 
  • Emotional stress related to fertility decisions 

Oncofertility specialists and counselling services can help women navigate these complex decisions. 

Breast Cancer and IVF 

Some women require IVF (in vitro fertilisation) for infertility after breast cancer treatment. A common concern is whether IVF fertility injections could increase the risk of breast cancer developing or returning. 

IVF involves hormonal stimulation to encourage the ovaries to produce multiple eggs. Because these medications can temporarily increase oestrogen levels, some women worry about the potential link with breast cancer. 

Current research suggests that IVF does not significantly increase breast cancer risk in the general population. It appears to be safe in women with a history of breast cancer, even hormone receptor positive breast cancer. It also appears to be safe in those with inherited genetic mutations, such as BRCA1 or BRCA2. However individual risks may differ and personalised advice from specialists should always be sought when considering IVF after breast cancer. 

Consulting both a fertility specialist and an oncology team can help ensure treatment plans are safe and appropriate. Some women require multiple IVF cycles to retrieve enough eggs. Current evidence does not link repeated egg retrieval cycles with an increase in breast cancer recurrence risk. However, long-term data on this topic remains limited. 

Individualised medical advice is recommended when planning fertility treatment. 

Do repeated egg retrieval cycles increase breast cancer risk?

Current research does not show strong evidence that repeated egg retrieval cycles or fertility treatments increase the risk of developing breast cancer or of breast cancer recurring. While these treatments involve short-term rises in hormones like oestrogen, no clear long-term link with breast cancer has been established.  

If you are considering egg freezing or IVF, it’s important to speak with your oncologist and fertility specialist to understand your individual risk and options. 

Breast Cancer During Pregnancy

Although uncommon, breast cancer during pregnancy can occur. International estimates suggest it affects around 1 in 3,000 pregnancies. 

Pregnancy does not cause breast cancer. However, hormonal changes and normal breast changes during pregnancy can sometimes make diagnosis more difficult. 

For this reason, any breast lumps or unusual change should be assessed promptly, even during pregnancy. 

When breast cancer is diagnosed during pregnancy, treatment decisions are made by a multidisciplinary team, including oncologists, obstetricians and surgeons experienced in caring for pregnant patients. 

Can breast cancer during pregnancy affect the baby?

Breast cancer itself does not spread to the baby and many treatments can still be safely given during pregnancy with careful monitoring. 

For example: 

  • Surgery is generally safe during pregnancy 
  • Chemotherapy may be possible during the second and third trimesters 
  • Radiotherapy and hormone therapy are usually delayed until after birth 

Close monitoring throughout pregnancy helps ensure both maternal and foetal health. 

Treatment Options for Breast Cancer During Pregnancy 

Breast cancer treatment during pregnancy requires careful planning to balance effective cancer treatment with the safety of the developing baby. 

  • Surgery – Breast surgery is generally considered safe during all stages of pregnancy but is ideally performed after the first trimester. Procedures may include lumpectomy or mastectomy depending on the cancer type and stage.
  • Chemotherapy – Chemotherapy is usually avoided during the first trimester, when the baby’s organs are forming. However, chemotherapy may be safely given during the second and third trimesters under specialist supervision. For more information on chemotherapy during pregnancy, view our dedicated article. 
  • Radiotherapy during pregnancy – Radiotherapy is typically postponed until after delivery because radiation exposure may harm the developing baby.
  • Endocrine therapy and pregnancy – Hormone therapies used to treat hormone-receptor-positive breast cancer are not recommended during pregnancy and are usually started after birth. Targeted therapy during pregnancy – Many targeted therapies are also avoided during pregnancy due to potential risks to the baby. Treatment decisions are always tailored to the individual situation. 

Birth Control After Breast Cancer Treatment

Women who have completed breast cancer treatment may still need reliable contraception, particularly while taking endocrine therapy. 

For women with hormone receptor-positive breast cancer, as well as those with HER2-positive or triple negative breast cancer, hormone-based contraceptives are generally avoided. These contraceptives contain oestrogen or progesterone, which may not be suitable after breast cancer treatment. Your healthcare team can recommend the most appropriate contraception option based on your individual circumstances. 

Non-hormonal options may be recommended, such as: 

  • Copper intrauterine device (IUD) 
  • Condoms or barrier methods 
  • Fertility awareness methods in some cases 

Choosing the right contraception method should always involve discussion with a healthcare professional. 

Breast Cancer Research and Fertility in Australia

Research continues to improve fertility options for women diagnosed with breast cancer. 

Australian researchers and organisations such as Breast Cancer Trials are contributing to important studies on: 

Clinical trials such as POEMS have already helped improve fertility outcomes for many women. 

Women interested in advancing research may consider discussing clinical trial participation with their healthcare team. 

Frequently Asked Questions

  • Can I get pregnant after breast cancer treatment?

    Many women can conceive after breast cancer treatment. Fertility and breast cancer outcomes depend on age, treatment type and ovarian function. Speaking with a fertility specialist can help assess individual options. 

  • Does IVF increase the risk of breast cancer?

    Current research does not show a strong increase in breast cancer risk for most women undergoing IVF, including in the context of breast cancer and IVF. However, personalised advice is recommended as individual risks will vary. 

  • Can chemotherapy cause permanent infertility?

    Chemotherapy and fertility are closely linked, as chemotherapy can affect ovarian function. Some women experience temporary infertility, while others may develop early menopause or permanent infertility. The risk of early menopause and permanent infertility increases with age. 

  • Is it safe to become pregnant after breast cancer?

    Research suggests pregnancy after breast cancer does not increase recurrence risk for most women, but timing and individual circumstances should be discussed with healthcare professionals.  

  • What birth control can I use after breast cancer?

    Non-hormonal contraception, such as copper IUDs or barrier methods, is often the recommended birth control after breast cancer especially for women with hormone-receptor-positive breast cancer. 

  • Can you have breast cancer while pregnant?

    Yes, although it is uncommon. Breast cancer during pregnancy requires specialist care but many treatments can still be safely given.  

  • Does breastfeeding stop breast cancer?

    No. Breastfeeding does not treat or stop breast cancer. However, breastfeeding has been associated with a small reduction in breast cancer risk for the mother over their lifetime. The ability to breastfeed after treatment depends on the type of surgery and treatments received. 

  • Information Sources

    1. https://pmc.ncbi.nlm.nih.gov/articles/PMC9955856/ 
    2. https://www.cancer.gov/types/breast/breast-cancer-during-pregnancy  
    3. https://pubmed.ncbi.nlm.nih.gov/34197218/ 
    4. https://pubmed.ncbi.nlm.nih.gov/29087485/ 
    5. https://jamanetwork.com/journals/jama/fullarticle/2812828 

Join Our Free Q&A Webinars

Don’t miss an opportunity to stay informed about the latest in breast cancer research and care. Join our FREE Q&A webinars, where we cover important topics including whether more young women are being diagnosed with breast cancer.

Stay Connected with Breast Cancer Trials

Don’t miss an opportunity to stay informed about the latest in breast cancer research and care. Sign up to our researcher’s newsletter via the form below to stay up to date.

Name(Required)

SIGN UP TO RECEIVE OUR FREE RESEARCH NEWSLETTER

Latest Articles

fertility, pregnancy and breast cancer

Fertility, Pregnancy and Breast Cancer

study hints at immunotherapy benefit for trastuzumab-resistant her2-positive breast cancer 
split-banner-image

Study Hints at Immunotherapy Benefit for Trastuzumab-Resistant HER2-Positive Breast Cancer

The addition of immunotherapy drugs to the treatment regimen for advanced HER2-positive breast cancer, may improve progression-free survival in women with oestrogen receptor-positive disease or with tumours carrying an immune protein called PD-L1. 

Speaking at the European Society for Medical Oncology conference in May 2025, researchers presented early results from the DIAmOND study, which explored the effects of adding two types of checkpoint inhibitor drugs to standard treatment with trastuzumab; a drug commonly used to treat HER2-positive breast cancer. 

The Australian study enrolled 72 patients with advanced HER2-positive breast cancer, whose disease was progressing despite treatment, and divided them into three treatment groups. 

Two groups – one consisting of people with oestrogen receptor-positive (ER+) disease and one consisting of those with oestrogen-receptor negative (ER-) disease – received a combination of two checkpoint inhibitors, tremelimumab and  durvalumab, plus trastuzumab.  

The third group of people with ER+ or ER- disease received an initial single dose of tremelimumab, then continued treatment with durvalumab and trastuzumab. 

At one year, those who received the initial priming dose of tremelimumab had the highest rate of progression-free survival, at 27%, followed by women with ER+ disease at 16%. However, in women with ER- disease, progression-free survival rates were just 8%. 

The results also suggested that the immunotherapy approach was more effective in women with PD-L1+ disease, as progression-free survival rates were highest – 67% – in women with cancer that was both ER+ and PD-L1+. 

Checkpoint inhibitors have been extraordinarily effective in treating lung and skin cancers, because they remove the tumour’s blockade of the immune system, and therefore allow it to attack the tumour. 

Tremelimumab and durvalumab achieve this through different modes of action. Durvalumab interacts with the PD-L1 protein that is found on the surface of cancer cells, while tremelimumab targets another tumour protein called CTL-4, which works to suppress the immune response to the tumour. Researchers hoped that the combination of the two approaches would be more effective that one or the other by themselves. 

Checkpoint inhibitors are associated with known side effects. Around two-thirds of those in group one and group two experienced severe adverse events, but the rate of severe events was slightly lower in the third group who received the initial priming dose of tremelimumab. 

While the study is small, and the numbers of individuals in each treatment group even smaller, the researchers said the results suggest that targeting both CTLA-4 and PD-L1 with immunotherapy does have an effect in women with disease that was progressing despite trastuzumab therapy. 

“Promising signals were seen in ER-positive and PD-L1 positive patients, and further investigation of dual checkpoint blockade plus HER2-targeted therapies is warranted,” they wrote. 

Publication: 

Loi S, Zdendowski N, Gebski V, Li I, Wilcken N, Morris M, Vatandoust S, Redfern AD, Blum FH, Stoodley I, Long S, Hay T, Hui R. Primary efficacy results of tremelimumab and durvalumab in combination with trastuzumab in trastuzumab resistant advanced HER2-positive breast cancer: BCT1703 DIAmOND. ESMO Open 2025; 10 (suppl 4) DOI: https://doi.org/10.1016/j.esmoop.2025.104873 301MO 

SIGN UP TO RECEIVE OUR FREE RESEARCH NEWSLETTER

Latest Articles

fertility, pregnancy and breast cancer

Fertility, Pregnancy and Breast Cancer

study hints at immunotherapy benefit for trastuzumab-resistant her2-positive breast cancer 
split-banner-image

Palbociclib Shows No Difference in Quality of Life in Early-Stage ER-Positive Breast Cancer 

A study finding a lack of benefit from palbociclib in women with earlier stage oestrogen receptor-positive breast cancer, sheds important light on the drug’s place in breast cancer treatment. 

Palbociclib is a CDK4/6 inhibitor, which compromises cancer cells’ ability to divide and multiply. It has been trialled successfully in people with metastatic oestrogen receptor-positive, HER2-positive breast cancer, in whom it was shown to significantly slow down cancer progression. 

The PALLAS study investigated whether adding palbociclib to standard hormone-blocking endocrine therapy might improve the effectiveness of endocrine therapy and also maintain quality of life for women with early-stage breast cancer. 

This analysis, published in ESMO Open in June 2025, looked at data from nearly 4700 women with ER-positive, HER2-negative stage 2-3 breast cancer to receive either standard hormone blocking therapy plus palbociclib, or hormone blocking therapy alone. 

By the end of study however, researchers saw no significant differences between the two groups in invasive disease-free survival, nor in a range of quality of life measures including pain, fatigue, hot flashes, and hair loss. 

Medical oncologist Dr Nicholas Zdenkowski, Chair of the Breast Cancer Trials Scientific Advisory Committee – who was on the steering committee for the trial – said the lack of benefit from palbociclib stood in contrast to positive results for two other similar agents, ribociclib and abemaciclib.  

“There’s been a lot of thought put into why there might be a difference with palbociclib versus the others,” he said, but as yet that question is unanswered. 

While the overall results of PALLAS found no clinically significant improvements in symptoms and quality of life with palbociclib, there were trends that suggested some effects from the drug. Among women treated with palbociclib, the worsening of pain – particularly musculoskeletal pain – was delayed compared to those not on palbociclib, although those on the drug also experienced slightly more fatigue and hair loss. 

“The pain that is being discussed here is of musculoskeletal or arthritis-type pain that we commonly see with the aromatase inhibitor treatment, which is one of the types of standard endocrine therapy that we use,” Dr Zdenkowski said. “So we’ve seen an attenuation of that, and it’s not because it’s reducing the anti-cancer effect of those drugs.” 

Understanding why this class of drug might reduce some of the impact of endocrine therapy side effects could provide insight into how patients could stay on endocrine therapy longer, as these side effects are often a reason why patients stop treatment early.  

“By identifying ways of either managing those side effects or potentially coming up with new treatments that have fewer side effects, if we can keep patients on it and optimise their quality of life, then they’ll have better outcomes,” Dr Zdenkowski said. 

Publication: 

Bjelic-Radisic V, Solkner L, Demichele A, Naughton M, Lemieux J, Zdenkowski N, Ruiz Borrego M, Mao J, Shinn E, Singer CF, Meisel J, Chan A, Iwata H, Mamounas T, Loible S, Gauthier E, Dueck A, Hlauschek D, Mayer E, Gnant MI, on behalf of the PALLAS groups and investigators (ABCST, AFT, BIG, PReCOG, GBG, NASBP). Relationship between physician-graded symptomatic adverse events and patient-reported quality of life (QOL): An analysis of the phase III PALLAS trial. ESMO Open. 2025; 10 (4 suppl) DOI: https://doi.org/10.1016/j.esmoop.2025.104879 Abstract 307P 

SIGN UP TO RECEIVE OUR FREE RESEARCH NEWSLETTER

Latest Articles

fertility, pregnancy and breast cancer

Fertility, Pregnancy and Breast Cancer

study hints at immunotherapy benefit for trastuzumab-resistant her2-positive breast cancer 
split-banner-image

Palbociclib Boosts Progression-Free Survival in Triple-Positive Breast Cancer

The survival chances for women with ‘triple-positive’ breast cancer increase significantly with the addition of a drug called palbociclib, which compromises cancer cells’ ability to divide and multiply. 

The international PATINA trial, published in the New England Journal of Medicine in January 2026, involved 518 women with triple-positive breast cancer – cancers which express oestrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor (HER2) – that had spread, or metastasised, beyond the breast and lymph nodes. 

The standard of care for this type and stage of breast cancer is a combination of endocrine therapy drugs and HER2-directed therapies, such as pertuzumab and trastuzumab.  

The aim of the PATINA trial was to see if there could be additional benefits from adding another drug – palbociclib – to that regimen. Palbociclib inhibits the action of proteins that are critical for cancer cell growth, and previous studies had shown positive effects in women with ER-positive, HER2-negative breast cancer. 

“In terms of targeting the oestrogen receptor, one analogy is that endocrine therapy is akin to Batman and palbociclib is akin to Robin; the sidekick that works together with endocrine therapy to make it better and more effective,” said Professor Elgene Lim, a medical oncologist and researcher at the Garvan Institute of Medical Research in Sydney, who was the lead Australian investigator on the PATINA trial. 

The results were impressive. Women who were treated with the standard oestrogen-suppressing and HER2-targeting therapies achieved an average of 29.1 months without their disease getting any worse, but those who were also given palbociclib achieved an average of 44.3 months without progression. For some women, that meant their disease remained stable but others saw their tumours shrink, in some cases to the point where the cancer was no longer detectable. 

Professor Lim said 44 months without disease worsening was impressive. “This is an undoubtedly a success, and undoubtedly a benefit to these patients, because of that significant improvement in terms of progression-free survival,” he said. “We’ve rarely seen a situation where we’ve had this average duration of progression-free survival in any cancer in the metastatic setting.” 

Around 10 percent of the women in the study were based in Australia and some were Professor Lim’s patients. While the study itself only required five years of palbociclib treatment, around 28 percent of the women in the palbociclib treatment group chose to stay on the treatment. “Many patients of mine are still doing well after five years,” he said.  

Publication: 

Metzger O, Mandrekar S, Goel S, Gligorov J, Lim E, Ciruelos E, Loibl S, Dockter T, Gonzalez Farre S, Francis PA, Lynce F, Lanzillotti J, DuFrane C, Wall A, Strand C, Krop I, Vaz-Luis I, Tripathy D, oi S, Prat A, Goetz M, Escriva-de-Romani S, Porter D, Spoenlein J, Stover DG, Sardesai S, Heudel P, Koehler M, Huang Martlett C, Hoynskyj A, Gopalakrishna P, Gauthier E, Delaloge S, Miller K, Winer EP, Gianni L, Partridge AH, DeMichele A, Carey LA. Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer. New England Journal of Medicine 2026; 394  451-462 DOI: 10.1056/NEJMoa2511218 

SIGN UP TO RECEIVE OUR FREE RESEARCH NEWSLETTER

Latest Articles

fertility, pregnancy and breast cancer

Fertility, Pregnancy and Breast Cancer

study hints at immunotherapy benefit for trastuzumab-resistant her2-positive breast cancer 
split-banner-image

MRI Guides Better Treatment Decisions for Breast Cancer

The use of magnetic resonance imaging to examine newly diagnosed breast cancers provides valuable information that can change treatment, particularly in younger women with denser breasts, an Australian study has found. 

Cancer surgeon Professor Christobel Saunders, from Royal Melbourne Hospital and the Peter MacCallum Cancer Institute, has spent years pushing for Australian women to have the option of a Medicare-subsidised MRI as part of their initial cancer diagnosis. 

“It was particularly frustrating that you could get an MRI of your knee if you fell over playing football on a Saturday and have it funded, but if you had breast cancer, you couldn’t get an MRI,” Professor Saunders said. 

Now Professor Saunders and colleagues have completed a prospective trial involving 387 women from across NSW, Victoria and Western Australia, all of whom had been diagnosed with breast cancer using conventional methods but who clinicians felt would also benefit from having an MRI to guide treatment. 

The study, published in the Medical Journal of Australia in November 2025, showed that in just over half of cases, the information provided by the MRI led to a change in the breast cancer treatment plan.  

In 31% of cases, the MRI results prompted a change in surgical strategy, many from breast conserving surgery to mastectomy. The rate of mastectomies almost doubled after the MRI results were reviewed by surgeons, from 15% of women to 28%.  

“Most of that increased extent of surgery was justified, at least as far as we could tell from looking at the pathology reports,” Professor Saunders said. “In other words, the tumours were truly larger tumours or multifocal tumours.” 

The study also revealed that the majority changes in surgical management occurred in women under the age of 70, which Professor Saunders says reflects the fact that older women tend to have less dense breasts that can be more clearly imaged using conventional mammograms, and who therefore aren’t likely to benefit from the additional MRI.  

Another aim of the study was to examine who doctors chose to recommend for an MRI and why. Researchers saw that the most common reason for MRI was high breast density, which can make cancers harder to image using conventional methods. Other common reasons for recommending MRI were if the doctor noted a difference in tumour size from previous imaging, if the woman had multiple tumours, or if she was under 50 years of age. 

Women overwhelmingly were satisfied with the additional test, which gave them greater confidence in treatment decisions, Professor Saunders said. “We hope now that the government will continue to support MRI for women newly diagnosed with breast cancer going forward.” 

Publication: 

Marinovich ML, Houssami N, Spillane A, Mann GB, Taylor D, Reintals M, Phillips N, Bulsara MK, Soon PSH, Dickens T, Saunders CM. Changes in patient management after preoperative MRI for newly diagnosed breast cancer: a multicentre prospective observational study. Medical Journal of Australia. 2025; 223 (11) 602-610 epub 24 Sept 2025. doi: 10.5694/mja2.70051. 

SIGN UP TO RECEIVE OUR FREE RESEARCH NEWSLETTER

Latest Articles

fertility, pregnancy and breast cancer

Fertility, Pregnancy and Breast Cancer

study hints at immunotherapy benefit for trastuzumab-resistant her2-positive breast cancer 
split-banner-image

FINER Study Points to Benefits from Ipatasertib in Treatment-Resistant Hormone Sensitive Breast Cancer

For people with hormone-receptor-positive breast cancer whose disease has spread despite treatment with hormone-blocking therapy, the standard treatment approach so far has been simply to continue with different forms of hormone therapy. 

Now a study suggests that also targeting a key cell-growth pathway with a drug called ipatasertib in these patients, could achieve significant improvements in progression-free survival compared to hormone therapy alone.  

One of the mechanisms by which breast cancers develop resistance to hormone therapy is mutations in genes coding for the PI3K/AKT pathway, which is a cell signalling pathway essential for cell growth. Dysfunctions in this pathway are implicated in a range of diseases including cancer.  

Ipatasertib is an AKT inhibitor, which means it specifically targets the same AKT pathway in cancer cells and disrupts it, which stops cancer cells from replicating. 

The FINER study involved 250 people from Australia, Canada and New Zealand with oestrogen receptor-positive, HER2-negative breast cancer. All those in the study had already received treatment with the standard dual therapy of a CDK4/6 inhibitor plus an aromatase inhibitor, but their cancer had spread.  

The participants were randomised to either receive treatment with ipatasertib plus the standard hormone therapy drug fulvestrant, or fulvestrant plus a placebo. After around 15 months of follow-up, researchers found evidence suggesting that the ipatasertib therapy was significantly slowing down progression of the cancer.  

Those who were treated with ipatasertib plus fulvestrant had a median of 5.3 months before their disease progressed, compared to a median of 1.9 months in the group treated with fulvestrant only. 

Researchers also looked at a subset of participants whose tumours showed evidence of having a mutation in the AKT pathway, and compared their outcomes after ipatasertib treatment with those of participants without those mutations. This revealed that the AKT pathway altered patients had a median of 5.45 months before their disease progressed, compared to 1.9 months in the unaltered group. 

There was a higher rate of side effects in the ipatasertib group, with 16% of patients experiencing diarrhoea compared to none of the placebo group, 3% experiencing fatigue, 2% experiencing vomiting, and 2% reporting rash.  

The research team said the results suggest that adding ipatasertib to standard therapy for this patient group significantly prolongs progression-free survival compared to standard therapy alone, but more follow-up and analysis is needed to understand the longer-term effects, and how the combination works with different breast cancer subtypes. 

Publication: 

Chia SKL, Redfern AD, Ayoub J-BM, Chalchal HI, Rayson D, Rushton M, Desbiens C, Sabanathan D, Raphael J, Chan A, Singh J, Simmons CE, Zdenkowski N, Wilson S, Rodin D, Cescon DW, Schimmoller F, Gallinaro L, Chen BE, Paralekar WR. A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2-negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT04650581). Journal of Clinical Oncology. 2025; 43 (suppl 17).  Abstract LBA1005. 

SIGN UP TO RECEIVE OUR FREE RESEARCH NEWSLETTER

Latest Articles

fertility, pregnancy and breast cancer

Fertility, Pregnancy and Breast Cancer

study hints at immunotherapy benefit for trastuzumab-resistant her2-positive breast cancer 
split-banner-image

Breast Cancer Recurrence Risk Drops Significantly if Hormone Therapy Extended Beyond Five Years

People with oestrogen receptor-positive breast cancer who extend their hormone-blocking therapy treatment beyond the standard five years by switching to, or continuing treatment with an aromatase inhibitor drug, could further reduce the risk of their cancer returning. 

In August 2025, the international Early Breast Cancer Trialists’ Collaborative group published a meta-analysis in the Lancet, in which they combined and analysed the data from 12 randomised controlled trials involving more than 22,000 postmenopausal women with hormone-sensitive early stage breast cancer. 

All women had already had at least five years of hormone-blocking therapy with either tamoxifen or another class of drugs called aromatase inhibitors, and were cancer-free at the entry to the study. The meta-analysis then looked at what happened to women who continued their treatment beyond five years compared to those who didn’t. Researchers saw a significant benefit from continuing treatment for up to an extra five years, and particularly if that continued treatment was with an aromatase inhibitor. 

The greatest benefits were seen in women who had previously received five years of tamoxifen therapy then switched to an aromatase inhibitor for a further one to four years of treatment. Their relative risk of recurrence in those one to four years was almost halved compared to the risk in women not taking any continued hormone blocking therapy. 

In women who were originally treated with aromatase inhibitors, a further five years of the same treatment reduced their risk of recurrence by 26% compared to those who didn’t continue treatment. Even taking the additional aromatase inhibitor therapy for two to three years reduced the risk of recurrence. 

Medical oncologist Dr Nicholas Zdenkowski, Chair of the Breast Cancer Trials Scientific Advisory Committee, said it was important to show a benefit from extended therapy, to enable decisions in the clinic at the five-year mark to allow clinicians and patients to understand options to minimise recurrence risk.  

There needs to be a shared decision-making approach to weigh up the pros and cons, he said, because of the side effects that may be experienced with aromatase inhibitor treatment, which include hot flushes, insomnia, vaginal dryness, fatigue, bone density loss and arthritis. 

“We need to make sure that if we’re going to offer these patients treatment for longer than five years, that we’re benefiting them in doing so,” Dr Zdenkowski said. “This shows that an additional five years beyond their standard five years achieves a statistically significant improvement in disease-free survival, irrespective of their baseline risk.” 

The benefit of extended treatment was even greater among women with a higher risk of recurrence at the start of the study because their cancer had already spread to the nearby lymph nodes. 

“If they’ve got higher risk node-positive disease, and there’s more a 5% absolute difference in benefit, then they may be more motivated to continue despite the side effects,” Dr Zdenkowski said.  

Publication: 

Early Breast Cancer Trialists Collaborative Group (EBCTCG). Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22031 postmenopausal women already treated with at least 5 years of endocrine therapy. The Lancet. 2025; 406 (10503) 603-614 epub 7 August 2025 

SIGN UP TO RECEIVE OUR FREE RESEARCH NEWSLETTER

Latest Articles

fertility, pregnancy and breast cancer

Fertility, Pregnancy and Breast Cancer

study hints at immunotherapy benefit for trastuzumab-resistant her2-positive breast cancer 
split-banner-image

ASCO 2026: BREAST CANCER RESEARCH SUMMARY

A summary of the key breast cancer research presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

Highlights from the 2026 ASCO Annual Meeting

The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the most important events in the global cancer calendar, where researchers and clinicians gather to share the latest advances in cancer care. This year’s conference, held in Chicago, featured exciting developments in breast cancer research — many of which are expected to change treatment options and improve outcomes for women diagnosed with the disease.

Here are some of the key highlights from ASCO 2026, summarised for our community.

OPTIMA

The OPTIMA clinical trial has found that many people with breast cancer can safely avoid chemotherapy with the use of a tumour gene test, potentially sparing them unnecessary side effects without increasing the risk of the cancer returning.

OPTIMA was designed to safely reduce the use of unnecessary chemotherapy for people with newly diagnosed breast cancer. It followed more than 4,400 patients worldwide and Breast Cancer Trials coordinated the trial in Australia and New Zealand, where 263 patients participated in the study.

The findings indicate that people aged 40 and over, whose tumours have a low Prosigna test score, can be treated safely with hormone blocking therapy alone, potentially transforming care for thousands of patients each year. Of the 4,429 people who took part in the trial, more than two-thirds (68%) had a low Prosigna score. For this group, the results showed that outcomes were very similar whether chemotherapy was given or not. Five years after treatment:

  • 91.5% of those who received standard chemotherapy alongside hormone blocking therapy were alive and free from breast cancer recurrence
  • 90.4% of those who received treatment based on the Prosigna test were also alive and recurrence-free, with 2/3 able to avoid chemotherapy

A statistical test showed that at the most, only 2% of patients with a low Prosigna score treated with chemotherapy will benefit from this treatment. This means that many patients will safely be able to be spared unnecessary side effects of chemotherapy.

CAPTURE

The CAPTURE clinical trial has concluded that one of the current standard of care options – chemotherapy with capecitabine – in metastatic breast cancer patients whose cancer has progressed on prior hormone blocking therapy, continues to be an effective treatment.

The study aimed to discover if women and men with hormone-receptor positive metastatic breast cancer may have benefited from a novel combination of drugs designed to improve progression free survival and offer a new treatment option.

While it was hoped that this new treatment would result in better breast cancer control for these patients, the trial showed that the outcomes were not superior to the current standard of care, which we know is an effective, well-tolerated option.

CAPTURE was coordinated by Breast Cancer Trials in Australia and New Zealand, involved 58 participants at 22 sites and was open to both men and women.

LidERA

The lidERA study tested a new hormone therapy drug called giredestrant in people with early-stage hormone receptor-positive (ER-positive), HER2-negative breast cancer, the most common type of breast cancer. After surgery and any necessary chemotherapy, patients usually take hormone-blocking medicines for several years to reduce the risk of the cancer returning. Researchers wanted to know whether giredestrant could do a better job than today’s standard hormone treatments.

More than 4,100 patients from around the world took part in the trial. Participants were randomly assigned to receive either giredestrant or standard hormone therapy, such as an aromatase inhibitor or tamoxifen.

The results were very encouraging. Patients taking giredestrant had a 30% lower relative risk of invasive breast cancer returning or death compared with those receiving standard hormone therapy. The benefit was seen across a range of patient groups, including both premenopausal and postmenopausal women.

Importantly, giredestrant was generally well tolerated. Side effects were similar to those seen with standard hormone therapies, and fewer patients stopped treatment because of side effects compared with the standard treatment group.

In simple terms, lidERA is the first large study in more than two decades to show that a new type of hormone therapy can outperform current standard treatments in early-stage ER-positive breast cancer. If approved, giredestrant could become a new option to help reduce the risk of breast cancer returning after initial treatment.

GPL-1 Drugs and Breast Cancer Recurrence

Several observational studies presented at ASCO 2026 suggested a possible link between GLP-1 medicines and better breast cancer outcomes, generating considerable interest among researchers.

The studies focused on GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), medicines commonly used to treat diabetes and obesity. Researchers analysed large real-world databases to explore whether people taking these drugs experienced different cancer outcomes compared with similar patients not taking them.

One study involving more than 100,000 women found that those taking GLP-1 medicines were about 30% less likely to be diagnosed with breast cancer. Other analyses suggested that people with breast cancer and several other obesity-related cancers who were taking GLP-1 drugs were less likely to progress to advanced or metastatic disease. In breast cancer specifically, one analysis reported about a 43% lower risk of progression to stage 4 disease compared with a matched control group.

Researchers believe the benefits may be related to weight loss, reduced inflammation, improved insulin regulation, or possibly direct effects on cancer-related pathways. However, the studies were observational and cannot prove that the drugs themselves caused the improved outcomes.

In simple terms, the ASCO 2026 findings suggest that GLP-1 medicines may do more than help people lose weight—they could potentially reduce the risk of breast cancer developing, recurring, or spreading. However, definitive proof will require prospective clinical trials, several of which are now being planned.

This was one of the most talked-about “emerging stories” at ASCO 2026 because it raises the possibility that drugs already used by millions of people could eventually become part of strategies to improve breast cancer outcomes. However we are not yet at the stage where doctors would prescribe GLP-1 drugs specifically to prevent breast cancer recurrence.

SENOMAC

The SENOMAC study examined whether many women with early breast cancer can safely avoid a more extensive operation in the underarm area after cancer is found in one or two sentinel lymph nodes. Traditionally, finding cancer in these lymph nodes led to an axillary lymph node dissection (ALND), a procedure that removes many additional lymph nodes but can cause long-term side effects such as arm swelling (lymphoedema), pain, numbness and reduced arm movement.

The study included more than 2,500 patients from five European countries, making it the largest trial of its kind. Researchers compared patients who underwent the standard ALND with those who did not have further lymph node surgery after a positive sentinel node biopsy.

The results were very reassuring. After five years of follow-up, survival rates were virtually identical between the two groups. Overall survival was 94.4% in patients who avoided ALND and 93.4% in those who underwent the procedure, showing that skipping the extra surgery did not compromise cancer outcomes.

Importantly, patients who avoided ALND experienced significantly fewer long-term arm problems and better arm function. Severe arm-related disability was much less common, and patients reported better quality of life related to arm symptoms.

In simple terms, SENOMAC showed that many patients with limited cancer spread to the underarm lymph nodes can safely avoid extensive lymph node surgery without affecting their chances of survival. This means fewer long-term side effects and a better quality of life, while maintaining excellent cancer control.

AXSANA

The AXSANA study looked at whether women with breast cancer who have cancer in their underarm (axillary) lymph nodes before treatment can safely avoid extensive lymph node surgery after receiving chemotherapy before surgery. Traditionally, many of these patients undergo an axillary lymph node dissection, which removes many lymph nodes but can cause long-term side effects such as arm swelling (lymphoedema), pain and reduced shoulder movement.

AXSANA followed more than 3,000 patients across Europe who received chemotherapy before surgery. Researchers evaluated different approaches to assessing the lymph nodes afterwards, including less invasive procedures such as targeted axillary dissection, where only the lymph nodes known to have contained cancer and a small number of key “sentinel” nodes are removed.

The results showed that less extensive surgery was increasingly being used in patients whose lymph nodes appeared cancer-free after treatment, with very low rates of cancer returning in the underarm area during follow-up. The findings provide reassurance that many patients can safely avoid full lymph node dissection when they respond well to treatment before surgery.

Importantly, reducing the extent of surgery can help lower the risk of complications, particularly lymphoedema, which can significantly affect quality of life long after cancer treatment has finished.

In simple terms, AXSANA supports a growing shift toward less invasive surgery for the underarm in selected breast cancer patients. By tailoring surgery to how well the cancer responds to treatment, doctors may be able to achieve the same cancer control while reducing long-term side effects and improving quality of life.

NCT01019616

The NCT01019616 study focused on people with hormone receptor-positive (HR-positive), HER2-negative breast cancer who still had cancer remaining in the breast or lymph nodes after receiving chemotherapy before surgery. These patients are known to have a higher risk of the cancer returning, and doctors have long debated whether giving additional chemotherapy after surgery can improve outcomes.

The study enrolled 400 women in China with lymph node-positive breast cancer. After surgery, patients were randomly assigned to receive either standard hormone therapy alone or additional chemotherapy followed by hormone therapy. The chemotherapy used was deliberately different from the drugs patients had already received before surgery, in an attempt to overcome treatment resistance.

The updated results presented at ASCO 2026 showed that adding this “non-cross-resistant” chemotherapy led to improved long-term survival outcomes compared with hormone therapy alone. The benefits were seen in reducing the risk of cancer returning and translated into improved overall survival with extended follow-up.

In simple terms, this study suggests that for some patients whose breast cancer does not respond well to initial chemotherapy, switching to a different type of chemotherapy after surgery may provide an additional chance to reduce the risk of recurrence and improve survival. The findings support a more personalised approach, where treatment decisions are guided by how the cancer responds to earlier therapy rather than using the same strategy for everyone.

One caveat is that this was a study conducted in a specific patient population before many of today’s newer targeted treatments became widely available, so doctors will consider these results alongside modern treatment options.

SAKK REDUSE

The SAKK REDUSE study looked at whether people with breast cancer that has spread to the bones could receive denosumab (a drug that helps strengthen bones and reduce complications) less often without losing its benefits. Traditionally, denosumab is given every four weeks, but researchers wanted to know if giving it every 12 weeks after an initial treatment period would work just as well.

The study enrolled 1,380 patients with either metastatic breast cancer or advanced prostate cancer involving the bones. Participants were randomly assigned to continue the standard four-week schedule or switch to a 12-week schedule after an initial loading phase. Researchers then tracked serious bone-related complications such as fractures, spinal cord compression, or the need for surgery or radiation to the bones.

The results were very reassuring. Patients receiving denosumab every 12 weeks had almost exactly the same protection against bone complications as those receiving treatment every four weeks. The study met its main goal, showing that the less frequent schedule was not inferior to the standard approach.

Importantly, patients on the 12-week schedule experienced fewer side effects, including lower rates of low calcium levels and osteonecrosis of the jaw, a potentially serious dental complication. They also required fewer clinic visits and treatments.

In simple terms, SAKK REDUSE showed that many patients with breast cancer that has spread to the bones can receive denosumab every three months instead of every month without compromising effectiveness, while reducing side effects, treatment burden and healthcare costs. The investigators concluded that the 12-week schedule should become a new standard of care for these patients.

ASCENT-03

The ASCENT-03 study evaluated whether sacituzumab govitecan (Trodelvy), a targeted cancer treatment known as an antibody-drug conjugate, could work better than standard chemotherapy as the first treatment for people with advanced triple-negative breast cancer (TNBC) who were not suitable candidates for immunotherapy. This is an important group of patients because treatment options are often limited and outcomes can be poor.

More than 550 patients from around the world took part in the study. Participants were randomly assigned to receive either sacituzumab govitecan or standard chemotherapy. The goal was to see which treatment could keep the cancer under control for longer.

The results were very encouraging. Patients treated with sacituzumab govitecan experienced a 38% reduction in the risk of their cancer worsening or death compared with those receiving chemotherapy. The study met its primary goal and showed a clear improvement in the length of time patients lived without their cancer progressing. Researchers also reported longer-lasting responses to treatment, with no unexpected safety concerns.

Additional analyses presented at ASCO 2026 showed that the benefits of sacituzumab govitecan were seen across a range of patient groups, regardless of tumour biomarkers such as Trop-2 expression, BRCA status or HER2-low status.

In simple terms, ASCENT-03 suggests that sacituzumab govitecan could become a new first-line treatment option for people with advanced triple-negative breast cancer who cannot receive immunotherapy, helping keep their cancer under control for longer than standard chemotherapy.

TROPION Breast-02

The TROPION-Breast02 study looked at a new targeted treatment called datopotamab deruxtecan (Dato-DXd) for people with advanced triple-negative breast cancer (TNBC), one of the most aggressive forms of breast cancer. The study focused on patients for whom immunotherapy was not considered a suitable option, leaving chemotherapy as the usual standard treatment.

Researchers compared Dato-DXd with standard chemotherapy in more than 600 patients who had not previously received treatment for their metastatic disease. Dato-DXd is an antibody-drug conjugate, meaning it is designed to deliver chemotherapy directly to cancer cells while limiting exposure to healthy cells.

The results were highly encouraging. Patients receiving Dato-DXd went a median of 10.8 months before their cancer worsened, compared with 5.6 months for those receiving standard chemotherapy. They also lived longer overall, with a median survival of 23.7 months versus 18.7 months. The treatment reduced the risk of cancer progression by 43% and the risk of death by 21% during the study period.

Importantly, patients receiving Dato-DXd reported maintaining their quality of life for longer, and side effects were generally manageable and consistent with previous studies of the drug.

In simple terms, TROPION-Breast02 showed that Dato-DXd may be a more effective alternative to standard chemotherapy for many people with advanced triple-negative breast cancer who cannot receive immunotherapy, helping them live longer while keeping their cancer under control for longer.

OASIS-4

The OASIS-4 study focused on a common but often overlooked challenge for people receiving hormone therapy for breast cancer: hot flushes, night sweats, poor sleep and other menopause-like symptoms. These side effects can be severe and sometimes lead patients to stop taking treatments that are important for reducing the risk of cancer recurrence.

Researchers tested a new non-hormonal medicine called elinzanetant in nearly 500 women with, or at high risk of developing, hormone receptor-positive breast cancer who were experiencing moderate to severe symptoms while taking endocrine (hormone) therapy. Participants received either elinzanetant or a placebo. This drug is considered safe after a diagnosis of breast cancer, because it does not affect the oestrogen receptor.

The results were very encouraging. Women taking elinzanetant experienced fewer and less severe hot flushes and night sweats, with improvements seen as early as the first week and sustained over time. The treatment also led to better sleep and improved quality of life compared with placebo.

Importantly, the drug was well tolerated, with a safety profile consistent with earlier studies. Longer-term analyses presented subsequently showed that benefits were maintained regardless of the type of hormone therapy patients were receiving.

In simple terms, OASIS-4 showed that a non-hormonal treatment may be able to significantly reduce some of the most troublesome side effects of breast cancer hormone therapy, helping patients feel better and potentially making it easier for them to stay on treatment for the recommended length of time.

SERENA-6

The updated SERENA-6 results presented at ASCO 2026 strengthened evidence for a new approach to treating advanced hormone receptor-positive, HER2-negative breast cancer. Researchers regularly monitored patients’ blood for early signs that their cancer was becoming resistant to treatment. When a resistance-related change (an ESR1 mutation) was detected, patients switched to the investigational drug camizestrant while continuing their existing targeted therapy.

The benefits seen in the original analysis were maintained with longer follow-up. Patients who switched early had a median of 16.8 months before their cancer worsened, compared with 9.2 months for those who stayed on standard treatment. The study also showed that benefits extended beyond the first progression, delaying the need for subsequent treatments and more intensive therapies.

Quality of life remained well maintained, and side effects were generally manageable. Researchers also found that cancer-related DNA in the bloodstream was much more likely to disappear in patients who switched to camizestrant, suggesting stronger control of the disease.

In simple terms, SERENA-6 continues to support the idea that regular blood testing may be able to identify treatment resistance before scans show cancer growth. If longer term results are consistent, this may allow doctors to change treatment earlier with the goal of keeping the disease under control for longer.

If you would like to stay up to date with research news, sign up to our monthly research newsletter (linked below).

HOST A PINK BLOOM PARTY FOR BREAST CANCER AWARENESS MONTH

Latest Articles

fertility, pregnancy and breast cancer

Fertility, Pregnancy and Breast Cancer

study hints at immunotherapy benefit for trastuzumab-resistant her2-positive breast cancer 
split-banner-image

MASTECTOMY RECOVERY

Learn what to expect during mastectomy recovery, including healing timelines, recovery tips, emotional support and when to contact your doctor.

A mastectomy is a major breast cancer surgery that involves removing one or both breasts to treat or reduce the risk of developing breast cancer. While it is a common and often effective treatment, the decision to have a mastectomy can feel overwhelming. Many people, including men and women, describe the lead-up to surgery as one of the most emotionally and practically challenging periods of their breast cancer journey.  

Emotionally, preparing for a mastectomy can bring up feelings of fear, uncertainty, grief, and anxiety. You may be processing the shock of a recent diagnosis, thinking about how your body will change, or wondering how you’ll cope physically and emotionally afterwards. It’s normal to experience concerns about body image, intimacy, sexuality, and identity – alongside worries about the surgery itself.  

Practically, there’s a lot to manage as well. From organising time off work and understanding your surgical options, to preparing your home environment, arranging support, and navigating pre-operative appointments, the planning phase can feel like a full-time job. Many people also find themselves juggling childcare, family responsibilities, financial considerations, and coordinating help for the first few weeks at home.  

Understanding what mastectomy recovery involves – physically, emotionally, and practically – can help you feel more prepared and supported. This article walks you through what to expect before and after surgery, tips for navigating recovery, and insights from people who’ve been there. If you’re still deciding about surgery, read our guide explaining types of mastectomy and reconstruction options. 

Mastectomy types and their impact on recovery 

Single mastectomy recovery

Single mastectomy recovery is generally more straightforward than a double mastectomy because only one side of the chest needs to heal. This means less discomfort, fewer limitations in arm movement, and a quicker return to daily tasks.    

Double mastectomy recovery

With a double mastectomy, because both sides of the chest are healing at once, women typically experience more pain, tightness, and fatigue during the early weeks. Arm mobility can be significantly reduced, making everyday activities, like getting out of bed, reaching overhead, or dressing, more challenging at first but many women regain strength and mobility steadily with guided exercises and appropriate follow-up care.   

Mastectomy recovery timeline: what to expect 

Recovery happens in phases, and no two people heal in the same way. The below timeframes are general guidelines only. 

0–2 weeks: Immediate post-op 

  • Hospital stay of 1–2 days 
  • Some level of pain is expected, as well as swelling, bruising, tightness and limited arm movement 
  • Surgical drains may be in place 
  • No heavy lifting until advised by your doctor 
  • Rest, gentle walking, and wound care are prioritised 
  • Wear a breast binder or post-surgical bra 
  • Watch for signs of infection, including redness, increased swelling, warmth, pus or fever 

2–6 weeks: Short-term healing 

  • Gradual return to everyday activities 
  • Increased arm mobility 
  • Fatigue and emotional shifts are common 
  • Follow your surgeon’s guidance on driving and lifting 

6 weeks+: Long-term recovery and lifestyle adjustments 

  • Most women resume daily life and work (as appropriate) 
  • Scar healing, ongoing physiotherapy, and emotional adjustment 
  • Those with reconstruction may take longer to fully recover 
  • Fatigue can persist for several months 

“What I wish I knew before mastectomy”: real stories & reflections

Many women say the emotional side of recovery can be just as challenging as the physical. Some reflections include:  

“Recovery is not linear. It can feel like a roller coaster, with ups and downs along the way, and it will look different for everyone both physically and emotionally. Try not to compare your recovery to anyone else’s, be kind to yourself, and allow yourself to take the time you need to heal”- Katrina  

“Look into post operative physiotherapy options early, rather than waiting for issues to arise. Taking an active role in your recovery asking about safe exercise, mobility, and long-term function can make a meaningful difference. If something doesn’t feel right post op speak up.” – Katrina  

“I wish I knew before my mastectomy not to get caught up with buying multiple bras, in built bra tank tops and swimmers and then an array of pillows to assist post surgery. It all adds up financially and I know everyone is different, but for me it wasn’t necessary. It was panic buying in my case.” – Kate  

Emotional and mental preparation

It’s normal to feel anxious, uncertain, or overwhelmed while preparing for a mastectomy. Many women find this time emotionally challenging as they process how surgery may change their body and what it might mean for their sexuality and identity. 

Concerns about appearance, recovery, and what life will look like afterwards can all contribute to fear about life post mastectomy. These feelings are common and understandable. You should discuss any concerns that you have about your planned surgery with your treatment team. 

What to do before surgery

The most important thing before a mastectomy is to make sure that you understand the planned surgery, reconstruction options and likely recovery. Consider keeping a notebook with a list of questions to make sure you don’t forget to ask anything. 

There are also practical preparations that can help make the experience of surgery and recovery easier. Taking time to organise your home and arrange support can mean you head into surgery feeling more informed and in control and make the first weeks of recovery much easier.

Factors that affect mastectomy recovery

Every woman’s recovery is unique, and several medical and personal factors influence how quickly and comfortably you heal. These can affect your physical recovery timeline, your emotional wellbeing, and the type of support you may need after surgery. 

Why breast cancer stage affects mastectomy recovery

Recovery can vary based on breast cancer stage because: 

  • In early breast cancer when there is an emphasis on prompt treatment, emotional recovery may be more complex, especially if the cancer is aggressive or treatment decisions were made quickly. 
  • Locally advanced cancers may require more extensive surgery to the breast and axilla, such as an axillary clearance, which increases pain, swelling, and the risk of lymphoedema. 
  • Reconstruction timing may be influenced by stage: women needing radiation post-surgery may have delayed reconstruction, affecting both short and long-term recovery timelines. 
  • People with advanced cancer may also be undergoing chemotherapy or radiation therapy or have other cancer related symptoms which can slow wound healing and prolong fatigue. 
  • Other factors that influence recovery: 
    • Age and general health: Younger, fitter women often recover faster. Pre-existing conditions (diabetes, heart conditions, obesity) and cigarette smoking/vaping may slow healing. 
    • Type of mastectomy: Single, double, skin-sparing, nipple-sparing 
    • Axillary surgery: whether a sentinel lymph node biopsy or axillary clearance are performed. 
    • Reconstruction choices: Immediate reconstruction, especially flap surgery, increases initial recovery time.
      Complications: Infections, seromas, lymphoedema and cording (or axillary web syndrome) can prolong recovery. 
    • Seroma: pockets of fluid can develop in the immediate weeks after surgery. This can feel like a soft or hard swelling under the skin. Seromas often disappear by themselves over time but can sometimes need draining. 
    • Lymphoedema: a build-up of lymph fluid in the tissues because the lymphatic system is damaged, blocked, or not working as well as it should. This extra fluid causes swelling, heaviness, tightness, and discomfort often in the chest wall or arm. Unlike a seroma, it cannot be drained. 
    • Cording (axillary web syndrome): rope-like cords that appear under the skin of your inner arm. This can feel painful or tight and make it hard to lift your arm or straighten your elbow fully. 
    • Emotional health: Anxiety, trauma, or body image concerns may affect overall wellbeing and pace of recovery. 

Skin-sparing and nipple-sparing recovery

Physical recovery after a skin-sparing or nipple-sparing mastectomy is generally similar to a traditional mastectomy, though the preserved skin or nipple may need extra care as it heals. Emotionally, some women find the process easier because more of their natural breast contour is maintained, which can help with body image and adjustment. 

Practical tips for a smoother recovery

The fastest way to recover from a mastectomy is to follow the guidance of your treatment team, as they understand the specific needs of your surgery and overall health. While every woman’s recovery timeline is different, adopting healthy habits can support your healing, improve comfort, and help you regain strength more steadily. Many patients find that small, consistent actions make a meaningful difference in how they feel day to day. 

These additional habits contribute to a quicker recovery: 

  • Take medications as prescribed 
  • Practice deep breathing and coughing 
  • Sleep slightly upright on your back for the first few weeks to reduce pain and pressure on wounds and drains as well as reduce swelling  
  • Keep wound and drain sites clean 
  • Start gentle physiotherapy exercises as instructed 
  • Maintain hydration and balanced nutrition 
  • Reach out to your treatment team with any questions or if you need support 

Things you need after a mastectomy

Having the right items on hand can make your recovery more comfortable and help you move around with greater ease in the first few weeks after surgery. These practical tools and sources of support can reduce strain on your body, help manage pain or swelling, and provide emotional comfort during a challenging time. 

Your treatment team will provide you a list of items required to support your journey that is personalised to your situation.

Some additional items that may help physically or emotionally include: 

  • Comfort cushions or post-surgical cushions (you may be provided with a cushion whilst in hospital) 
  • Front-button shirts 
  • Soft wire-free bra. Front opening bras can be easier to use with limited arm mobility (you may be provided with a bra whilst in hospital) 
  • Drain care kit including a drain bag and cleaning supplies 
  • A journal for emotional processing 
  • Support from friends, family, or professionals.  

Home care after mastectomy

Caring for yourself at home is an important part of healing after a mastectomy. Establishing a simple routine for wound care, rest, and gradual movement can help prevent complications and support a smoother recovery. Your treatment team will give you specific instructions, but these are the common elements of home care: 

  • Regular wound checks 
  • Drain management 
  • Dressing changes 
  • Avoiding strenuous activity 
  • Good hygiene and rest 

When can you resume normal activities? 

Disclaimer: This information is general in nature and not a substitute for medical advice. Always consult your GP or treating specialists for guidance tailored to your own breast cancer diagnosis and recovery. 

Timelines vary widely from person to person, but these general guidelines can help manage expectations: 

  • Lifting your arms: It is ideal to limit overhead arm movement for up to 2 weeks post operatively, or longer if drains remain in place. Patients should also avoid lifting anything over 2kg for up to 6 weeks depending on your surgery. Always check with your surgeon for specific advice for your situation. 
  • Driving: Typically allowed after 2–3 weeks, once you can safely shoulder-check, turn the wheel, and are no longer taking strong pain medication. This is usually after your post-operative follow up appointment with your surgeon. It is important to feel confident before returning to driving – if you feel anxious about driving speak to your treatment team. 
  • Returning to work: Many women return to light duties between 4–6 weeks, but this is very dependent on the type of surgery and the type of work performed. Physically demanding jobs may require significantly more time off. 
  • Fatigue: Fatigue is very common after a mastectomy and can persist for several months which can affect when women feel ‘back to normal’ 

Personal variability and the importance of medical clearance 

Recovery looks different for everyone. Factors like age, overall health, the type of mastectomy, lymph node removal, and whether reconstruction was performed all affect how quickly you can return to normal activities. Some women feel ready within a few weeks, while others need several months due to pain, fatigue, or limited mobility.  

Because of these differences, medical clearance is advised before resuming activities such as lifting, driving, or strenuous movement. Your treatment team will assess wound healing, drain removal, shoulder mobility, and any signs of complications to determine what’s safe for you.  

Even if you feel ready, pushing too hard too soon can lead to setbacks. Follow-up appointments and physiotherapy help ensure you return to daily routines at a pace that protects your healing and long-term wellbeing. 

Emotional recovery

Emotional recovery is a real part of healing after a mastectomy, and it’s completely normal for it to feel just as challenging – sometimes more so – than the physical recovery. It can also take much longer than the physical healing and vary widely between individuals. 

Patients who have a mastectomy may experience sadness at the loss of a breast. They may also experience sexuality and identity shifts, as well as fears about recurrence.  

When possible, immediate breast reconstruction is thought to lead to improved psychological, emotional and social outcomes, as the patient wakes from their surgery with a new breast. But even with reconstruction it usually takes 3–12 months for women to feel better about their body image. 

Whilst it can be confronting, it is important to look at your chest after your surgery. This allows you to monitor your healing and detect any complications like seromas or infections. It also helps you adjust to your new body image. If you are anxious about seeing your new chest after your surgery, you should discuss this with your treatment team. 

It is important to discuss any difficulties with emotional recovery with your treatment team, and to consider engaging with counselling or psychology and peer support groups. 

Emotional and mental support options

Support is available in many forms, including counselling or psychology services to help you process emotions, peer support groups where you can connect with others who’ve had similar experiences, and breast care nurses who can provide guidance, reassurance, and practical advice throughout your treatment and recovery. Self-care strategies like eating well, resting adequately, exercising and practicing mindfulness and deep breathing exercises for if you feel anxious are also important to implement. 

You can read more about mental health and breast cancersexual health after breast cancer and other useful resources on our website.   

When to contact your doctor

It is important to monitor your symptoms closely after surgery, as early signs of complications can sometimes be subtle. Paying attention to changes in your body and contacting your treatment team promptly can help prevent small issues from becoming more serious. Most patients have follow up with their surgeon several weeks after their surgery, however you should seek additional medical advice if you notice: 

  • Redness, heat, swelling or pus around the wound 
  • Fever or chills 
  • Feeling generally unwell 
  • Sudden fluid build-up (possible seroma) 
  • Severe pain not controlled by medication 
  • Restricted shoulder or elbow movement 
  • Issues with drains 
  • Attend all follow-up appointments to stay on track with your recovery

Returning to work after mastectomy

Returning to work after a mastectomy is an important milestone for many women, but the timing can vary widely depending on the type of surgery, your overall health, your job demands, and how you’re feeling physically and emotionally. Most women return to work somewhere between 4–8 weeks after surgery, although some may require longer – especially after a double mastectomy or reconstruction. 

Physical readiness:

Before going back to work, asses your physical readiness and whether you can comfortably manage the physical demands of your role. Some questions you can ask yourself are: 

  • Can you sit, stand, or move comfortably for extended periods? Prolonged sitting or repetitive arm movements can feel tiring or uncomfortable in early recovery. 
  • Is your arm and shoulder mobility adequate? Many jobs require reaching, lifting, or turning – activities that may still be restricted. 
  • Are you still experiencing significant pain or fatigue? Fatigue can linger for weeks and even months, especially if you’re also undergoing reconstruction or other treatments. 
  • Has your treatment team cleared you? Your surgeon or breast care nurse will assess wound healing, scar tissue, and your overall movement before advising whether it’s safe to return. 

Women with physically demanding jobs (e.g., nursing, childcare, hospitality, retail, or roles involving lifting) may need a longer recovery period or modified duties. 

Emotional Readiness:

Going back to work is not just a physical decision – it’s also an emotional one. It’s very important to assess your emotional readiness. Many women experience a range of feelings, including: 

  • Anxiety about how colleagues will respond 
  • Concerns about your new appearance, especially after going flat and even after reconstruction 
  • Reduced confidence or difficulty concentrating 
  • Feeling overwhelmed or fatigued by social or sensory environments 

It’s helpful to ask yourself: 

  • Do I feel emotionally supported and ready for social interaction? 
  • Can I manage stress without feeling overwhelmed? 
  • Do I need more time to rest or adjust before returning to routine? 

Emotional readiness can be just as important as physical readiness, and it’s okay to request more time if you need it. 

Tips for a phased return to work

A gradual return can help you rebuild strength, confidence, and stamina without overwhelming yourself. Here are some options to consider: 

Reduced hours or part-time return (e.g., mornings only for the first 1–2 weeks) 

  • Alternating work-from-home and in-office days, if possible 
  • Light duties that avoid lifting, overhead movement, or strenuous activity 
  • Scheduled rest breaks to manage fatigue 
  • Adjusting your workstation for better posture and comfort (e.g., ergonomic chair, monitor height adjustments) 

Many women find that easing back into their routine helps prevent setbacks and supports long-term recovery. 

Communicating with your employer

Clear and proactive communication can make your return much smoother. Here are some considerations: 

  • Letting your employer know about your expected timeline early, even if it may change 
  • Requesting adjustments based on your treatment team’s recommendations 
  • Discussing flexible arrangements, such as a phased return or modified duties 
  • Providing medical certificates or recovery plans if required 
  • Setting boundaries, such as not lifting heavy items or avoiding tasks that strain your upper body 

If you’re unsure how much detail to share, focus on the functional impact rather than the personal specifics. For example: 

“My doctor has advised that I avoid lifting and overhead reaching for the next few weeks. I may need modified duties until I regain full mobility.” 

Many workplaces are supportive when they understand what you need and why. 

Final tips: what patients say helped the most

Many women say that accepting help early, wearing loose clothing, and keeping a simple rest routine made recovery easier. Gentle movement can ease stiffness and connecting with others who’ve been through a mastectomy often provides valuable reassurance and practical advice.  

If you’d like to support research that improves breast cancer treatment options, please consider donating to Breast Cancer Trials. 

Frequently Asked Questions

  • How long does it take to recover from a mastectomy?

    Recovery after a mastectomy happens gradually over several weeks and months, and the timeline can vary depending on the type of surgery and whether reconstruction is involved.  

    Most women spend 1–2 days in hospital, with the first 1–2 weeks focused on rest, managing pain and drains, and gently improving mobility. By 2–6 weeks, swelling and discomfort usually lessen, and many women feel ready to resume light activities, including driving or returning to work in non-physical roles.  

    Full recovery from a mastectomy can take up to 3 months.  especially after flap surgery-as  there are additional surgical sites and more complex healing.  

    Your recovery may be faster or slower depending on factors such as age, general health, whether lymph nodes were removed, and any complications or additional treatments like chemotherapy or radiation.  

  • Can you live a normal life after a mastectomy?

    Yes. Most women go on to live full, active, and healthy lives after a mastectomy. Once recovery is complete, many return to work, exercise, and their usual routines. Long-term outcomes are generally very positive – women often regain strength and mobility,  and adapt well to body changes with support, physiotherapy, and self-care. While some changes in sensation or scarring may remain, these rarely prevent a fulfilling, normal life.  

  • How does a woman feel after a mastectomy?

    Feelings range from grief and numbness to relief and empowerment. Persisting physical sensations like tightness or numbness are common. Counselling and support groups can help process these very normal feelings.  

  • What are the restrictions after mastectomy?

    Common restrictions include no heavy lifting, driving, or strenuous activity for at least several weeks. Your surgeon will give specific guidance based on your surgery and individual recovery prospects such as age and health.  

  • What special items are required by mastectomy patients?

    Items such as mastectomy bras, drain management kits and comfort cushions can significantly improve comfort and recovery by reducing pressure on healing tissues, supporting proper posture, keeping surgical drains secure, and helping you rest in positions that minimise pain and swelling. These small adjustments can make everyday movements easier and promote smoother, safer healing.  

  • How long do I have to sleep sitting up after a mastectomy?

    Most women need to sleep sitting up or at an incline or on their side for 1–2 weeks after a mastectomy. This position helps reduce swelling, protects surgical sites and drains, and makes it easier to get in and out of bed without straining the chest or arms. Using supportive items such as pillows or a recliner chair can make resting more comfortable and promote smoother healing. You can gradually transition to a flatter position once your surgeon confirms it’s safe.  

  • How traumatic is a mastectomy?

    A mastectomy can be both physically and emotionally challenging. Pain, tightness, fatigue, and changes in sensation are common early on and can feel overwhelming, but these usually improve over time. Emotionally, many women experience grief, anxiety, or difficulty adjusting to changes in appearance, which are normal responses.  

    Coping strategies such as gentle movement, relaxation, talking with loved ones, and connecting with others who’ve had a mastectomy can help. Professional support can also be valuable. With time, support, and self-care, most women adjust well and regain confidence. 

Join Our Free Q&A Webinars

Don’t miss an opportunity to stay informed about the latest in breast cancer research and care. Join our FREE Q&A webinars, where we cover important topics including whether more young women are being diagnosed with breast cancer.

Stay Connected with Breast Cancer Trials

Don’t miss an opportunity to stay informed about the latest in breast cancer research and care. Sign up to our researcher’s newsletter via the form below to stay up to date.

Name(Required)

SIGN UP TO RECEIVE OUR FREE RESEARCH NEWSLETTER

Latest Articles

fertility, pregnancy and breast cancer

Fertility, Pregnancy and Breast Cancer

study hints at immunotherapy benefit for trastuzumab-resistant her2-positive breast cancer 
split-banner-image

MASTECTOMY: TYPES AND RECONSTRUCTION

Learn about mastectomy surgery, including types of mastectomy, when it is recommended, and reconstruction options for breast cancer treatment.

What is a mastectomy?

A mastectomy is a surgical procedure to remove the entire breast, usually performed to treat breast cancer or substantially reduce the risk of developing it. Patients may choose or need to have a mastectomy for several reasons, including: 

  • Treating early and locally advanced breast cancer that is still localised to the breast and surrounding lymph nodes 
  • Reducing risk in people with high-risk genetic mutations that predispose to developing breast cancer (e.g., TP53, BRCA1 and BRCA2) 
  • Treating breast cancer that has recurred in the breast after previous treatment 
  • Rarely, people with advanced breast cancer that has spread beyond the breast and surrounding lymph nodes may also have a mastectomy to manage problems such as chronic cancer wounds 

Mastectomy vs. lumpectomy: what’s the difference?

The two main surgical options for managing breast cancer are mastectomy and lumpectomy, also known as a partial mastectomy or breast conserving surgery. 

  • Mastectomy removes the whole breast. 
  • Lumpectomy, or breast conserving surgery, removes only the tumour and a small margin of surrounding normal breast tissue. It usually requires post operative radiotherapy to treat the remaining breast tissue. 
  • The right option depends on cancer stage, tumour size, genetic risk, and personal preference. 

When is a mastectomy recommended

A mastectomy can be recommended for a range of reasons including: 

  • The tumour is large and there will be little normal breast tissue left after removal of the cancer, resulting in breasts that are significantly different sizes.  
  • There are multiple tumours in different areas of the breast and removal of all the tumours would result in breasts that are significantly different shapes and sizes. 
  • There is a large area of ductal carcinoma in situ (DCIS) that needs to be removed to reduce the risk of developing breast cancer 
  • The person has a high-risk genetic mutation that predisposes to developing breast cancer (e.g., BRCA1/2) 
  • They prefer mastectomy to reduce future breast cancer risk 
  • They wish to avoid post mastectomy radiotherapy to the breast (noting this may still sometimes be required depending on tumour factors) 

Many women with early-stage breast cancer (stage 0-II) can choose between lumpectomy and mastectomy and still have optimal treatment of their breast cancer. This is often paired with a sentinel lymph node biopsy which involves removal of only the first draining lymph nodes in the axilla (armpit), which is a lesser surgery with quicker recovery time than an axillary clearance.  

Women with locally advanced breast cancer (stage III) may be recommended to have a mastectomy, especially if the tumour is larger and not suitable for lumpectomy. These women often have cancer that has spread to multiple lymph nodes and requires removal of all the lymph nodes in the armpit, called an axillary clearance. An axillary clearance is a more extensive surgery than a sentinel lymph node biopsy that can increase the risk of complications like lymphoedema and prolong recovery time. 

Inflammatory breast cancer is a rare, aggressive type of breast cancer that doesn’t present as a lump but instead causes the breast to be red, swollen and tender due to cancer cells blocking lymph vessels in the skin. This is ideally treated with pre-operative chemotherapy, followed by a mastectomy to ensure that the entirety of the cancer is removed.  

risk-reducing mastectomy is preventative (prophylactic) mastectomy due to high genetic risk or a strong family history of breast cancer.  This means it is performed because of the risk of breast cancer, not because a woman has breast cancer. Recovery may be physically easier because lymph nodes are typically not removed and there are no cancer-related symptoms to manage. 

Men and mastectomies

Men can also be diagnosed with breast cancer, which is commonly treated with a mastectomy as they have less breast tissue than women, meaning a lumpectomy may not be possible. Although breast cancer is less common in men, the physical and emotional impact of surgery can be just as significant. Men may face unique challenges, including delayed diagnosis, feelings of isolation, or a lack of awareness that breast cancer can affect them. Recovery after a mastectomy involves both physical healing and emotional adjustment, and men benefit from the same supports as women – clear information, medical guidance, and access to counselling or peer support. 

Who can I talk to about my treatment options? 

Your breast surgeon, breast care nurse, oncologist, or GP can guide you through benefits and risks, helping you make decisions aligned with your goals and values. 

 Types of mastectomy

The type of mastectomy you have can significantly influence your physical healing, emotional adjustment, and overall recovery after mastectomy. Each surgical option has its own benefits, considerations, and timelines for getting back to everyday life. Understanding these differences can help you prepare for the days, weeks, and months following your operation. 

Single vs. double mastectomy 

Single mastectomy

A single mastectomy involves removing one breast. This is usually all that is required for treatment of breast cancer, particularly if there is a low level of concern regarding development of cancer in the remaining breast. 

Double mastectomy

A double mastectomy removes both breasts and results in a longer and more demanding recovery. This usually occurs because of cancer in one breast and significant concerns about developing cancer in the other breast. Women can have breast cancer in both breasts at the same time, but it is rare. 

Emotionally, some women find reassurance in removing both breasts, especially if they are at higher genetic risk, while others may need more time to adjust to the changes in their body. 

Breast reconstruction options: with or without breast reconstruction

Your recovery will also vary depending on whether you choose reconstruction, the type of reconstruction performed and the timing of reconstruction. 

No breast reconstruction (“going flat”)

No breast reconstruction, also known as flat closure and “going flat”, often results in: 

  • A shorter operation 
  • Fewer surgical sites (incisions) 
  • A generally quicker recovery from mastectomy 
  • Fewer risks related to implants or flap surgery 
  •  Emotional recovery may take time as you adjust to a changed chest shape 

Decisions to consider: reconstruction vs going flat 

Choosing between reconstruction and going flat is a personal decision shaped by lifestyle, body image, and what feels right for you. Going flat offers a simpler surgery and recovery, which some women prefer, though adjusting to a flat chest can take time emotionally. 

Reconstruction can help restore breast shape and support body confidence for some, but it usually involves more extensive surgery and a longer healing process. Speaking with your surgeon, GP or breast care nurse can help you understand which option best aligns with your goals and comfort. 

Women who choose to ‘go flat’ also have non-surgical options including breast prostheses to recreate the shape of the breast without reconstruction. Prostheses are worn inside specialised bras and even swimwear and come in a range of sizes and weights that can be customised to the woman. There are government subsidies towards the cost of prostheses. 

Types of breast cancer reconstruction

There are 2 main types of reconstruction options, implant-based reconstruction and autologous flap reconstruction: 

  • Implant-based reconstruction (using silicone or saline implants) 
  • Autologous flap reconstruction (using tissue from another area of the body, such as the abdomen, back, or thighs) 

Implant based reconstruction can sometimes require a tissue expander which is a temporary device placed under the chest muscle or skin that is gradually filled with saline or air to allow the tissue to stretch prior to insertion of the permanent implant. 

Flap reconstruction has a longer recovery time as this surgery involves removing tissue from a separate part of the body (e.g abdomen in a DIEP flap) and attaching it to the chest wall to create the new breast shape.  This is more complicated surgery which can involve additional drains and more complex wound care, extend hospital stays, and restrict activity for several weeks. 

Single verses double reconstruction

Recovery time for bilateral reconstruction after double mastectomy is typically longer than going flat or having a single reconstruction after mastectomy on one side only. This is because surgery is required to both sides of the chest which means more time needed for healing and return to normal mobility and function. 

Immediate breast reconstruction 

Immediate reconstruction is performed during the same surgery as your mastectomy. Whilst this means that both the mastectomy and reconstruction are performed in the one surgery, it increases surgery time which may not be safe for patients with poorer general health. Immediate reconstruction also increases healing time which is not always ideal for more aggressive cancers that require treatment with post-operative chemotherapy. Some breast cancers also require post-operative radiation treatment which is preferrable to give prior to reconstruction.

Delayed reconstruction

Some women choose reconstruction months or years later. 

  • A shorter initial mastectomy recovery period  
  • More time to consider reconstruction options  
  • Flexibility if further treatment (like radiation) is needed 

Skin-sparing and nipple-sparing mastectomies 

Skin-sparing and nipple-sparing mastectomies are specialised surgical techniques designed to preserve as much of the breast’s natural appearance as possible. 

  • Skin-sparing mastectomy removes the breast tissue but keeps most of the overlying breast skin. 
  • Nipple-sparing mastectomy goes a step further by also preserving the nipple and areola, if it is safe to do so based on the location and type of cancer. 

These approaches are often used when a woman chooses immediate reconstruction because the preserved skin and sometimes the nipple, provides a natural envelope for an implant or flap, resulting in a more natural-looking outcome. 

Patient perspectives: deciding on a mastectomy

“Don’t be afraid to ask questions even the ones that feel small or repetitive. Appointments can be overwhelming, and it’s easy to forget what you wanted to ask once you’re in the room. Writing a list beforehand and taking it with you can be incredibly helpful. If possible, bring someone along to your appointment. These conversations can be emotionally charged, and having another person there to listen, absorb the information, and help relay it back to you later when you have the mental space can make a difference. Your medical team is there to support you, and advocating for yourself isn’t being difficult; it’s being informed.”– Katrina 

“I wish I knew before my mastectomy not to get caught up with buying multiple bras, in built bra tank tops and swimmers and then an array of pillows to assist post surgery. It all adds up financially and I know everyone is different, but for me it wasn’t necessary. It was panic buying in my case”. – Kate 

“After two years, I had a breast reconstruction. This was the best decision. Not only did the reconstruction make me feel physically whole again, it also improved my self-confidence and emotional wellbeing. I had completely underestimated how much a reconstruction would help me heal mentally and emotionally. So, with the benefit of hindsight, I would have planned my reconstruction as early as practical.” – Merryn 

Read Merryn’s full story here. 

I wish I knew before my mastectomy that I didn’t have to rush the decision about reconstruction. And I did feel that it was a rushed decision. It’s difficult making that decision about reconstruction when you have no hair, feeling like a drugged up alien and when you’re exhausted and emotional. I found lots of resources supporting reconstruction but little about what it’s like to either wait after all treatment is completed before making a decision or about being flat permanently. I knew what the scarring would look like and a discussion about external prosthesis but little about the emotional aspect of being flat. And that’s what I needed to know, how other women dealt with the emotional side.  Kate  

These stories highlight the importance of preparing for physical, emotional, and lifestyle changes. 

Sources:

https://www.bcna.org.au/resources/articles/breast-cancer-in-men

https://nbcf.org.au/about-breast-cancer/further-information-on-breast-cancer/breast-cancer-in-men/

https://www.cancer.org.au/types-of-cancer/breast-cancer/breast-cancer-in-men

Join Our Free Q&A Webinars

Don’t miss an opportunity to stay informed about the latest in breast cancer research and care. Join our FREE Q&A webinars, where we cover important topics including whether more young women are being diagnosed with breast cancer.

Stay Connected with Breast Cancer Trials

Don’t miss an opportunity to stay informed about the latest in breast cancer research and care. Sign up to our researcher’s newsletter via the form below to stay up to date.

Name(Required)

SIGN UP TO RECEIVE OUR FREE RESEARCH NEWSLETTER

HOST A PINK BLOOM PARTY FOR BREAST CANCER AWARENESS MONTH

Latest Articles

fertility, pregnancy and breast cancer

Fertility, Pregnancy and Breast Cancer

study hints at immunotherapy benefit for trastuzumab-resistant her2-positive breast cancer 
split-banner-image

CHEMOTHERAPY DURING PREGNANCY AND BREAST CANCER

Can you have chemotherapy while pregnant? Learn what Australian guidelines say about breast cancer treatment during pregnancy and risks to baby. 

Being diagnosed with breast cancer during pregnancy, or gestational breast cancer, can feel overwhelming, raising many urgent questions about treatment and the health of your baby. One of the most common concerns is whether chemotherapy during pregnancy is possible or safe. 

The reassuring news is that treatment decisions are carefully guided by medical evidence and Australian clinical guidelines. In many cases, chemotherapy can still be given during pregnancy, particularly in the later stages. When treating breast cancer in pregnancy, both cancer specialists and obstetric teams work closely to protect the health of both mother and baby. Understanding how chemotherapy is used during pregnancy can help you feel more informed and supported when making decisions about your care.  

Breast Cancer During Pregnancy

Breast cancer during pregnancy can be uncommon, but it can occur. It is estimated to affect around 1 in 3,000 pregnancies worldwide.

During pregnancy, the body produces higher levels of hormones such as oestrogen, which stimulate breast development to allow breast feeding. The mother’s immune system also changes to allow the growth of the baby. These and other factors can lead to the development of breast cancer during pregnancy. Normal breast changes during pregnancy – such as swelling, tenderness and increased breast density – can also make cancer harder to detect early. As a result, some women may be diagnosed at a slightly later stage. 

Even when diagnosed during pregnancy, many women can still receive effective cancer treatment. In some situations, chemotherapy may be recommended as part of treatment while pregnant, depending on the stage of breast cancer while pregnantthe type of breast cancer, and how far the pregnancy has progressed. 

Is Chemotherapy Safe During Pregnancy?

A key question many people ask is: is chemotherapy safe during pregnancy? 

The answer depends largely on the stage of pregnancy. 

Medical guidelines state that chemotherapy is not recommended during the first trimester, because this is when the baby’s organs are developing. Exposure to chemotherapy drugs during this early stage may increase the risk of miscarriage or birth defects. 

However, research and clinical experience show that most chemotherapy used in the treatment of breast cancer can often be safely given during the second trimester and third trimesters, when the baby’s major organs have already formed. At this stage, the risk of harm to the unborn baby is significantly lower. 

This approach allows doctors to continue treating the cancer without waiting until after delivery. 

Some other breast cancer treatments, such as trastuzumab, endocrine (hormonal) therapy such as tamoxifen and immunotherapy such as pembrolizumab, are not recommended for use at any stage during pregnancy due to risks to the baby. Doctors also carefully check which symptom control medications, like anti-nausea medications, can be safely given during pregnancy. 

For more information about treatment guidelines during breast cancer, visit Cancer Australia. 

What Trimester Can You Have Chemotherapy? 

The timing of chemotherapy during pregnancy is carefully planned. In general: 

Chemotherapy in first trimester (weeks 1–12): 

  • Chemotherapy is not recommended. 
  • This is when the baby’s organs are developing, so exposure to chemotherapy carries the greatest risk. 

Chemotherapy in second trimester (weeks 13–27): 

  • Chemotherapy is commonly given during the second trimester. 
  • The baby’s organs have already formed, reducing the risk of major birth defects. 

Chemotherapy in third trimester (weeks 28–birth): 

  • Chemotherapy may still be given in the third trimester, depending on the situation. 
  • Treatment is usually paused several weeks before delivery so that both mother’s and baby’s blood counts can recover and reduce the risk of complications during birth. 

Every pregnancy and cancer diagnosis is different, so the timing of treatment is tailored to each individual. 

How Does Chemotherapy Affect the Unborn Baby?

When chemotherapy is given during the first trimester, it can interfere with early organ development which may increase the risk of miscarriage or birth defects. This is why it is avoided during this stage of pregnancy. 

When chemotherapy is given after the first trimester, research suggests that most babies are born healthy. However, some risks can still occur, including: 

  • Lower birth weight 
  • A higher chance of early (preterm) delivery 
  • Temporary effects like low blood cell counts related to timing of chemotherapy administration 

Encouragingly, studies following children exposed to chemotherapy in the womb during the second or third trimester generally show normal growth and development. 

To minimise risks, pregnancies are closely monitored by specialists throughout treatment. 

Is Breast Cancer During Pregnancy More Aggressive? 

Breast cancer diagnosed during pregnancy can be more aggressive than breast cancer diagnosed in non-pregnant women. It can also be more advanced at diagnosis because pregnancy-related breast changes can make tumours harder to detect. Whilst the same types of breast cancer affect both pregnant women  and non-pregnant women, there are slightly higher rates of triple negative and HER2 positive breast cancers.  

This is why any unusual breast changes during pregnancy – such as a lump, skin changes, or nipple discharge – should be assessed promptly. 

Early assessment helps ensure that effective treatment can begin as soon as possible. 

What Happens If You Need Chemotherapy While Pregnant?

If chemotherapy is recommended during pregnancy, care is usually managed by a multidisciplinary medical team. This may include: 

  • Medical oncologists 
  • Obstetricians experienced in high-risk pregnancies 
  • Breast surgeons 
  • Specialist nurses and midwives 

Together, they create an individualised treatment plan that carefully balances cancer treatment with pregnancy care. 

This typically includes: 

  • Careful timing of chemotherapy cycles 
  • Regular monitoring of the baby’s growth 
  • Coordination of cancer treatment with the expected delivery date 
  • Emotional and psychological support 

For many women, this coordinated approach allows them to continue their pregnancy while receiving essential cancer treatment. 

Other breast cancer treatments and pregnancy 

There are other treatments that are a part of breast cancer management, including surgery and radiotherapy. 

Surgery for breast cancer, including have an anaesthetic is considered low risk after the first trimester.  

Radiotherapy poses a significant risk to the baby and is delayed until after the baby is delivered. 

Frequently Asked Questions

Can you have chemotherapy while pregnant?

Yes, in many cases chemotherapy can be given during pregnancy, particularly during the second and third trimesters. It is generally avoided in the first trimester due to risks to the developing baby. 

What trimester is chemotherapy safe during pregnancy?

Chemotherapy is usually considered safest during the second and third trimesters, when the baby’s organs have already developed. 

How does chemotherapy affect the unborn baby?

When given after the first trimester, most babies are born healthy. Possible risks include lower birth weight or early delivery, but long-term development is generally normal. 

Is breast cancer during pregnancy more aggressive?

Breast cancer diagnosed during pregnancy can be more aggressive. It can also be detected later because normal pregnancy changes can make tumours harder to detect. However, it is still very treatable with the care of multidisciplinary team. 

Can you breastfeed during chemotherapy?

No. Chemotherapy drugs can pass into breast milk and may harm the baby. Breastfeeding is not recommended while receiving chemotherapy. 

What are the treatment options when pregnant? 

Some treatments – such as endocrine (hormone) therapy, immunotherapy and certain targeted therapies – cannot be used during pregnancy. Chemotherapy may be used in later pregnancy if needed. Treatment plans are always personalised.  

What if you want to become pregnant after breast cancer treatment?

If you are thinking about pregnancy after treatment, watch our recorded Q&A webinar on fertility and breast cancer. Research such as the POSITIVE clinical trial is helping doctors understand how women taking endocrine therapy may safely pause treatment in order to attempt pregnancy under medical supervision. 

Find out more about recent research into interrupting endocrine therapy, to attempt pregnancy after breast cancer. 

Sources:

https://www.cancer.gov/types/breast/breast-cancer-during-pregnancy 

https://www.mdpi.com/1718-7729/31/4/171 

https://www.cancer.nsw.gov.au/about-cancer/document-library/gestational-breast-cancer-in-new-south-wales-a-pop

Join Our Free Q&A Webinars

Don’t miss an opportunity to stay informed about the latest in breast cancer research and care. Join our FREE Q&A webinars, where we cover important topics including whether more young women are being diagnosed with breast cancer.

Stay Connected with Breast Cancer Trials

Don’t miss an opportunity to stay informed about the latest in breast cancer research and care. Sign up to our researcher’s newsletter via the form below to stay up to date.

Name(Required)

SIGN UP TO RECEIVE OUR FREE RESEARCH NEWSLETTER

HOST A PINK BLOOM PARTY FOR BREAST CANCER AWARENESS MONTH

Latest Articles

fertility, pregnancy and breast cancer

Fertility, Pregnancy and Breast Cancer

study hints at immunotherapy benefit for trastuzumab-resistant her2-positive breast cancer 
split-banner-image

RACE FOR A CURE DRIVES RECORD FUNDS FOR BREAST CANCER TRIALS

Team Thryv & Race For A Cure has taken out first place in the 2026 Bathurst 6 Hour event, marking a major milestone not only on the track, but for life-saving breast cancer research.

Race For A Cure Drives Record Funds for Breast Cancer Trials

Team Thryv & Race For A Cure has taken out first place in the 2026 Bathurst 6 Hour event, marking a major milestone not only on the track, but for life-saving breast cancer research.

Over Easter weekend at the Bathurst 6 Hour, the Race For A Cure team took out 1st place, capping off an extraordinary campaign that continues to grow year-on-year. Following this year’s event, Race For A Cure has now raised more than $308,000 for Breast Cancer Trials which includes significant contributions from the team’s primary sponsor, Thryv.

Driven by supercar driver Thomas Randle alongside brothers Ben and Michael Kavich, the team’s first-place finish was described as an emotional and deeply meaningful achievement. Their campaign has always been about more than motorsport – it’s about turning personal experience into action.

Race For A Cure was born after the Kavich family’s mother, Toula, was diagnosed with breast cancer following the inaugural Bathurst 6 Hour in 2016. What started as a deeply personal journey has evolved into a powerful national fundraising movement, with more than $266,000 raised prior to this year’s event alone.

“Race For A Cure has always come from the heart,” explains Ben KavichWhat started as something deeply personal for our family has grown into a platform that lets us give back in a meaningful way and keep pushing for better outcomes for others facing breast cancer.”

The team’s impact goes beyond dollars raised. Their story resonates with patients, families and supporters across Australia and shows how communities can drive real change.

The Breast Cancer Trials team would like to extend our sincere thanks to the entire Race For A Cure team – Thomas Randle, Ben and Michael Kavich, their dedicated crew, partners and supporters – for their unwavering commitment to our mission.

Your passion and generosity continue to inspire us and so many others across Australia. By using your platform to raise awareness and vital funds, you are helping to drive forward life-saving research.

With a Bathurst 6 Hour win now added to their legacy, Race For A Cure continues to prove that motorsport can be a force for good. As the total fundraising figure climbs beyond $308,000 and counting, the team remains focused on what matters most: funding research that saves lives.

Learn more about Race For A Cure and donate here.

profile image

Race For A Cure

Race For A Cure is an annual initiative created by Ben, Toula and Michael Kavich. Ben and Michael participate in the Bathurst 6 Hour event held every Easter, raising both awareness and funds for the life-saving research conducted by Breast Cancer Trials.

Support Race For A Cure

Latest Articles

fertility, pregnancy and breast cancer

Fertility, Pregnancy and Breast Cancer

study hints at immunotherapy benefit for trastuzumab-resistant her2-positive breast cancer